MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-GJ-01-0012433
Market Cap
₹102 Cr
SOTAC-SM · NSE
Share Price
₹96.50
+4.89% today
Revenue
₹101 Cr
FY 2025-26 · +4.4% YoY
EBITDA
₹17.88 Cr
Margin 17.7%
Net Profit
₹5.76 Cr
FY 2025-26 · -25.1% YoY
P/E (TTM)
18.0x
P/B 1.7x
Authorised capital
₹11.5 Cr
Registered with MCA
Paid-up capital
₹11.05 Cr
Issued & subscribed
About Sotac Pharmaceuticals Limited
Data last updated:
Sotac Pharmaceuticals Limited is a public limited company based in Sanand, Gujarat, India. It operates in the chemical products segment of the chemicals sector. It was incorporated on 18 December 2015 and has been in existence for over 11 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24230GJ2015PLC085451. Its GSTIN is 24AAWCS5135M1ZP (Gujarat). The company holds 2 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on NSE: SOTAC.
The company has an authorised share capital of ₹11.5 Cr and a paid-up capital of ₹11.05 Cr. It is led by directors including Sharadkumar Dashrathbhai Patel (Managing Director) and Dineshkumar Babulal Gelot (Whole-Time Director).
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Plot No. Pf – 21 & Pf – 22/A, Charal Industrial Estate Sanand GIDC – II Sanand, Gujarat, India – 382110.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹101.24 Cr, a growth of 4.4% compared to the previous year. For the same year it recorded a net profit of ₹5.76 Cr (net margin 5.7%) and EBITDA of ₹17.88 Cr (EBITDA margin 17.7%). The net worth stands at ₹58.87 Cr (up 10.6% YoY). Total assets are valued at ₹102.32 Cr (up 0% YoY).
The company has about 37 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Sotac Pharmaceuticals. As per MCA filings, the company has open charges of ₹13.63 Cr and satisfied charges of ₹12.19 Cr on record. The company has 4 deals on record (1 secondary share transfer, 1 funding round, 1 ipo), with disclosed funding of ₹1.02 Cr; the latest was in April 2023. Its 8 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Pharma Impex Laboratories Pvt Ltd with revenue of ₹101.54 Cr. The company has 3 MSME Form 1 returns on record for the period ending Mar 2024, listing 146 overdue payments to 28 micro and small suppliers.
Sotac Pharmaceuticals Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-01-0012433). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sotacpharma.com.
Company details
CIN L24230GJ2015PLC085451
Registration Number 085451
Incorporation Date 18 December 2015
ROC Ahmedabad
Listing Status Listed (NSE: SOTAC)
Company Status Active
Date of Last AGM 29 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-GJ-01-0012433
CIN history
Sotac Pharmaceuticals has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24230GJ2015PLC085451, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230GJ2015PLC085451 | Current |
| U24230GJ2015PTC085451 | Previous |
| U24230GJ2015PLC085451 | Previous |
Key People
Sharadkumar Dashrathbhai Patel Managing Director Dineshkumar Babulal Gelot Whole-Time Director Chetankumar Bachubhai Patel Director Recognitions & Rankings of Sotac Pharmaceuticals
Contact details
Sotac Pharmaceuticals Limited's registered office is in Sanand, Gujarat.
- Social Media
- Registered AddressPlot No. Pf – 21 & Pf – 22/A, Charal Industrial Estate Sanand GIDC – II Sanand, Gujarat, India – 382110
- IndustryChemicals, Chemical Products, Medicinal Chemical & Botanical Products, Pharmaceuticals
Comprehensive company report
Sotac Pharmaceuticals Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Sotac Pharmaceuticals operates one associated brand: Sotac Pharmaceuticals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Finished formulations including capsules, tablets, and injectables are manufactured. | sotacpharma.com |
Business activity
The main business activity of Sotac Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Sotac Pharmaceuticals Limited, buy the company report.
Financials of Sotac Pharmaceuticals Limited
FY 2025-26 filings availableSotac Pharmaceuticals Limited reported revenue of ₹101.24 Cr (up 4.4% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹101 Cr
+4.4% YoY
EBITDA
₹17.88 Cr
+31.0% YoY
Profit After Tax
₹5.76 Cr
-25.1% YoY
Net Worth
₹58.87 Cr
+10.6% YoY
Total Assets
₹102 Cr
+0.0% YoY
Total Debt
₹37.60 Cr
-14.0% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 101 | 96.99 | 104 | 77.48 | 48.84 | 28.60 |
| Revenue growth | +4.4% | -6.6% | +34.0% | - | +70.8% | - |
| EBITDA | 17.88 | 13.65 | 8.32 | 7.89 | 1.46 | 1.87 |
| EBITDA margin | +17.7% | +14.1% | +8.0% | +10.2% | +3.0% | +6.5% |
| Profit before tax | 8.69 | 11.13 | 3.97 | 3.92 | (2.05) | 0.36 |
| Net profit | 5.76 | 7.69 | 4.33 | 2.54 | (2.36) | 0.08 |
| Net profit margin | +5.7% | +7.9% | +4.2% | +3.3% | -4.8% | +0.3% |
| EPS (₹) | 5.22 | 7.26 | 3.87 | 3.58 | (10.28) | 0.38 |
| Balance sheet | ||||||
| Total assets | 102 | 102 | 74.32 | 41.82 | 19.74 | 18.18 |
| Net worth | 58.87 | 53.25 | 45.26 | 19.46 | 2.49 | 3.06 |
| Total debt | 37.60 | 43.70 | 24.86 | 22.04 | 17.13 | 13.44 |
| Cash & bank | 1.18 | 1.56 | 3.42 | 9.68 | 0.27 | 0.43 |
| Net working capital | 46.53 | 47.77 | 29.64 | 15.60 | 2.26 | 1.55 |
| Cash flow | ||||||
| Cash from operations | 16.85 | (4.35) | (16.08) | 8.14 | (0.31) | 0.06 |
| Cash from investing | (6.90) | (13.62) | (19.68) | (11.67) | (3.23) | (11.75) |
| Cash from financing | (10.34) | 16.11 | 29.49 | 13.14 | 3.38 | 11.40 |
| Particulars | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 27.35 | 25.25 | 26.45 | 25.74 | 26.67 | 24.97 | 18.08 | 19.65 |
| Revenue growth (YoY) | +2.6% | +1.1% | +46.3% | +31.0% | -32.9% | - | - | - |
| Other income | 0.45 | 0.25 | 0.35 | 0.61 | 0.05 | 0.23 | 0.14 | 0.01 |
| EBITDA | 2.11 | 2.22 | 1.18 | 2.68 | 2.08 | 2.34 | 2.41 | 1.77 |
| EBITDA margin | +7.7% | +8.8% | +4.5% | +10.4% | +7.8% | +9.4% | +13.3% | +9.0% |
| Depreciation | 0.74 | 0.75 | 0.88 | 0.83 | 0.78 | 0.60 | 0.61 | 0.56 |
| Interest | 0.60 | 0.42 | 0.35 | 0.99 | 0.67 | 0.46 | 0.64 | 0.27 |
| Profit before tax | 1.22 | 1.30 | 0.30 | 1.47 | 0.68 | 1.51 | 1.30 | 0.95 |
| Tax | 0.79 | (0.05) | (1.21) | 0.59 | 0.47 | 0.52 | 0.27 | 0.37 |
| Net profit | 0.43 | 1.35 | 1.51 | 0.88 | 0.21 | 0.99 | 1.03 | 0.58 |
| EPS (₹) | 0.00 | 1.32 | 1.49 | 0.82 | 0.58 | 1.01 | 1.58 | 0.29 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 71.88 | 62.38 | 67.11 | 57.98 | 73.15 | 43.44 | 28.68 |
| Revenue growth | +15.2% | -7.1% | +15.8% | -20.7% | +68.4% | +51.5% | - |
| EBITDA | 9.12 | 7.67 | 9.98 | 8.23 | 6.18 | 2.87 | 1.98 |
| EBITDA margin | +12.7% | +12.3% | +14.9% | +14.2% | +8.5% | +6.6% | +6.9% |
| Profit before tax | 6.93 | 6.41 | 7.77 | 5.94 | 4.68 | 1.50 | 1.23 |
| Net profit | 4.92 | 4.76 | 5.93 | 4.47 | 4.56 | 1.50 | 1.18 |
| Net profit margin | +6.8% | +7.6% | +8.8% | +7.7% | +6.2% | +3.5% | +4.1% |
| EPS (₹) | 4.45 | 4.32 | 5.20 | 5.58 | 14.33 | 6.45 | 5.35 |
| Balance sheet | |||||||
| Total assets | 70.00 | 73.29 | 59.56 | 31.73 | 14.49 | 11.49 | 10.94 |
| Net worth | 57.82 | 53.03 | 48.27 | 20.99 | 7.10 | 4.81 | 3.70 |
| Total debt | 12.09 | 20.13 | 11.17 | 10.66 | 7.39 | 6.68 | 7.24 |
| Cash & bank | 0.34 | 0.45 | 0.64 | 9.60 | 0.03 | 0.02 | 0.04 |
| Net working capital | 37.80 | 42.90 | 30.22 | 13.57 | 5.86 | 3.22 | 2.49 |
| Cash flow | |||||||
| Cash from operations | 12.14 | (6.10) | (19.75) | 8.54 | 3.58 | 2.22 | - |
| Cash from investing | (2.30) | (1.89) | (12.53) | (10.93) | (3.28) | (1.07) | - |
| Cash from financing | (9.94) | 7.79 | 23.32 | 11.97 | (0.30) | (1.17) | - |
| Particulars | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 17.60 | 13.01 | 16.31 | 17.68 | 14.20 | 18.91 | 13.18 | 14.06 |
| Revenue growth (YoY) | +23.9% | -31.2% | +23.8% | +25.8% | -53.8% | - | - | - |
| Other income | 0.49 | 0.43 | 0.53 | 0.27 | 0.29 | 0.23 | 0.13 | 0.00 |
| Total expenses | 16.09 | 10.91 | 14.00 | 14.98 | 11.51 | 16.65 | 10.80 | 12.96 |
| EBITDA | 1.51 | 2.10 | 2.31 | 2.70 | 2.69 | 2.26 | 2.38 | 1.10 |
| EBITDA margin | +8.6% | +16.1% | +14.2% | +15.3% | +18.9% | +12.0% | +18.1% | +7.8% |
| Depreciation | 0.60 | 0.60 | 0.73 | 0.68 | 0.63 | 0.46 | 0.45 | 0.43 |
| Interest | 0.24 | 0.26 | 0.25 | 0.23 | 0.19 | 0.34 | 0.31 | 0.13 |
| Profit before tax | 1.16 | 1.67 | 1.86 | 2.06 | 2.16 | 1.69 | 1.75 | 0.54 |
| Tax | 0.31 | 0.42 | 0.48 | 0.56 | 0.48 | 0.48 | 0.51 | 0.02 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 27 Oct 2026
| Particulars | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 27.35 | 25.25 | 26.45 | 25.74 | 26.67 | 24.97 | 18.08 | 19.65 |
| Revenue growth (YoY) | +2.6% | +1.1% | +46.3% | +31.0% | -32.9% | - | - | - |
| Other income | 0.45 | 0.25 | 0.35 | 0.61 | 0.05 | 0.23 | 0.14 | 0.01 |
| EBITDA | 2.11 | 2.22 | 1.18 | 2.68 | 2.08 | 2.34 | 2.41 | 1.77 |
| EBITDA margin | +7.7% | +8.8% | +4.5% | +10.4% | +7.8% | +9.4% | +13.3% | +9.0% |
| Depreciation | 0.74 | 0.75 | 0.88 | 0.83 | 0.78 | 0.60 | 0.61 | 0.56 |
| Interest | 0.60 | 0.42 | 0.35 | 0.99 | 0.67 | 0.46 | 0.64 | 0.27 |
| Profit before tax | 1.22 | 1.30 | 0.30 | 1.47 | 0.68 | 1.51 | 1.30 | 0.95 |
| Tax | 0.79 | (0.05) | (1.21) | 0.59 | 0.47 | 0.52 | 0.27 | 0.37 |
| Net profit | 0.43 | 1.35 | 1.51 | 0.88 | 0.21 | 0.99 | 1.03 | 0.58 |
| EPS (₹) | 0.00 | 1.32 | 1.49 | 0.82 | 0.58 | 1.01 | 1.58 | 0.29 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|
| Revenue | 101 | 96.99 | 104 | 77.48 | 48.84 | 28.60 |
| Revenue growth | +4.4% | -6.6% | +34.0% | - | +70.8% | - |
| Other income | 0.35 | 3.90 | 0.49 | 0.35 | 0.11 | 0.22 |
| Total expenses | 83.36 | 83.34 | 95.51 | 69.59 | 47.38 | 26.73 |
| Employee cost | 0.00 | 1.61 | 2.05 | 2.58 | 2.50 | 1.36 |
| EBITDA | 17.88 | 13.65 | 8.32 | 7.89 | 1.46 | 1.87 |
| EBITDA margin | +17.7% | +14.1% | +8.0% | +10.2% | +3.0% | +6.5% |
| Depreciation | 5.41 | 3.84 | 3.10 | 2.28 | 2.59 | 1.40 |
| Interest | 4.13 | 2.58 | 1.74 | 2.04 | 1.03 | 0.33 |
| Profit before tax | 8.69 | 11.13 | 3.97 | 3.92 | (2.05) | 0.36 |
| Tax | 2.40 | 1.85 | 0.39 | 1.64 | 0.31 | 0.27 |
| Net profit | 5.76 | 7.69 | 4.33 | 2.54 | (2.36) | 0.08 |
| Net profit margin | +5.7% | +7.9% | +4.2% | +3.3% | -4.8% | +0.3% |
| EPS (₹) | 5.22 | 7.26 | 3.87 | 3.58 | (10.28) | 0.38 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 11.05 | 11.05 | 11.05 | 8.05 | 2.30 | 2.30 |
| Reserves & surplus | 47.82 | 42.20 | 34.21 | 1.94 | 0.19 | 0.76 |
| Shareholders' funds (net worth) | 58.87 | 53.25 | 45.26 | 19.46 | 2.49 | 3.06 |
| Minority interest | 5.70 | 5.17 | 4.07 | 0.23 | 0.07 | 1.66 |
| Secured loans | 30.05 | 31.28 | 23.46 | 21.89 | 14.36 | 9.54 |
| Unsecured loans | 7.55 | 12.42 | 1.40 | 0.15 | 2.77 | 3.90 |
| Total debt | 37.60 | 43.70 | 24.86 | 22.04 | 17.13 | 13.44 |
| Total liabilities | 102 | 102 | 74.32 | 41.82 | 19.74 | 18.18 |
| Assets | ||||||
| Gross block | 68.81 | 62.59 | 45.60 | 32.91 | 21.99 | 18.83 |
| Net block | 49.66 | 48.69 | 35.51 | 25.92 | 16.56 | 15.99 |
| Capital work in progress | 1.71 | 0.20 | 5.12 | 0.04 | 0.00 | 0.00 |
| Investments | 2.92 | 3.78 | 2.10 | 0.00 | 0.30 | 0.16 |
| Inventories | 27.08 | 20.26 | 18.01 | 13.64 | 4.83 | 2.32 |
| Sundry debtors | 32.95 | 34.11 | 26.29 | 14.74 | 5.88 | 6.96 |
| Cash & bank balances | 1.18 | 1.56 | 3.42 | 9.68 | 0.27 | 0.43 |
| Loans & advances | 16.47 | 13.89 | 12.93 | 9.08 | 6.20 | 3.88 |
| Total current assets | 77.68 | 69.82 | 60.65 | 47.14 | 17.18 | 13.59 |
| Total current liabilities | 31.15 | 22.05 | 31.01 | 31.54 | 14.92 | 12.04 |
| Net working capital | 46.53 | 47.77 | 29.64 | 15.60 | 2.26 | 1.55 |
| Total assets | 102 | 102 | 74.32 | 41.82 | 19.74 | 18.18 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|
| Opening cash | 1.56 | 3.42 | 9.68 | 0.08 | 0.43 | 0.72 |
| Net cash from operating activities | 16.85 | (4.35) | (16.08) | 8.14 | (0.31) | 0.06 |
| Net cash from investing activities | (6.90) | (13.62) | (19.68) | (11.67) | (3.23) | (11.75) |
| Net cash from financing activities | (10.34) | 16.11 | 29.49 | 13.14 | 3.38 | 11.40 |
| Net change in cash | (0.39) | (1.85) | (6.26) | 9.61 | (0.16) | (0.29) |
| Closing cash | 1.18 | 1.56 | 3.42 | 9.68 | 0.27 | 0.43 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | +4.4% | -6.6% | +34.0% | - | +70.8% | - |
| EBITDA growth | +31.0% | +64.1% | +5.5% | - | -21.9% | - |
| PBT growth | -21.9% | +180.4% | +1.3% | +9998.0% | - | +9997.0% |
| Net income growth | -25.1% | +77.6% | +70.5% | - | -3050.0% | - |
| Revenue CAGR (3Y) | +9.3% | +25.7% | +53.7% | - | - | - |
| EBITDA CAGR (3Y) | +31.4% | +110.7% | +64.5% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +6.2% | +9.6% | +3.5% | +2.9% | -4.8% | +0.3% |
| Return on capital employed | - | +16.4% | +10.2% | +13.0% | -5.7% | +3.9% |
| Return on net worth | - | +18.8% | +11.1% | +10.1% | -85.4% | +2.6% |
| Debt / equity | - | 0.70 | 0.72 | 1.13 | 5.51 | 4.39 |
| Long-term debt / equity | - | 0.27 | 0.31 | 0.40 | 2.78 | 2.01 |
| Interest cover | 33.12 | 26.30 | 33.33 | 36.36 | -91.15 | 70.21 |
| Efficiency & per share | ||||||
| Fixed asset turnover | - | 1.79 | 2.65 | 2.35 | 2.39 | 1.52 |
| Inventory turnover | - | 5.07 | 6.56 | 5.68 | 13.66 | 12.33 |
| Debtors turnover | - | 3.21 | 5.06 | 5.26 | 7.61 | 4.11 |
| EPS (₹) | 5.22 | 7.26 | 3.87 | 3.58 | (10.28) | 0.38 |
| Dividend per share (₹) | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 48.19 | 40.96 | 12.41 | 10.84 | 13.29 |
| Particulars | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 17.60 | 13.01 | 16.31 | 17.68 | 14.20 | 18.91 | 13.18 | 14.06 |
| Revenue growth (YoY) | +23.9% | -31.2% | +23.8% | +25.8% | -53.8% | - | - | - |
| Other income | 0.49 | 0.43 | 0.53 | 0.27 | 0.29 | 0.23 | 0.13 | 0.00 |
| Total expenses | 16.09 | 10.91 | 14.00 | 14.98 | 11.51 | 16.65 | 10.80 | 12.96 |
| EBITDA | 1.51 | 2.10 | 2.31 | 2.70 | 2.69 | 2.26 | 2.38 | 1.10 |
| EBITDA margin | +8.6% | +16.1% | +14.2% | +15.3% | +18.9% | +12.0% | +18.1% | +7.8% |
| Depreciation | 0.60 | 0.60 | 0.73 | 0.68 | 0.63 | 0.46 | 0.45 | 0.43 |
| Interest | 0.24 | 0.26 | 0.25 | 0.23 | 0.19 | 0.34 | 0.31 | 0.13 |
| Profit before tax | 1.16 | 1.67 | 1.86 | 2.06 | 2.16 | 1.69 | 1.75 | 0.54 |
| Tax | 0.31 | 0.42 | 0.48 | 0.56 | 0.48 | 0.48 | 0.51 | 0.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 71.88 | 62.38 | 67.11 | 57.98 | 73.15 | 43.44 | 28.68 |
| Revenue growth | +15.2% | -7.1% | +15.8% | -20.7% | +68.4% | +51.5% | - |
| Other income | 2.10 | 2.38 | 1.32 | 0.24 | 0.21 | 0.35 | 0.69 |
| Total expenses | 62.76 | 54.71 | 57.13 | 49.75 | 66.97 | 40.57 | 26.70 |
| Employee cost | 0.00 | 0.93 | 1.46 | 2.01 | 2.13 | 2.14 | 1.21 |
| EBITDA | 9.12 | 7.67 | 9.98 | 8.23 | 6.18 | 2.87 | 1.98 |
| EBITDA margin | +12.7% | +12.3% | +14.9% | +14.2% | +8.5% | +6.6% | +6.9% |
| Depreciation | 2.50 | 2.47 | 2.51 | 1.63 | 1.13 | 1.11 | 1.07 |
| Interest | 1.79 | 1.17 | 1.02 | 0.90 | 0.58 | 0.61 | 0.37 |
| Profit before tax | 6.93 | 6.41 | 7.77 | 5.94 | 4.68 | 1.50 | 1.23 |
| Tax | 2.01 | 1.64 | 2.01 | 1.47 | 1.40 | 0.00 | 0.00 |
| Net profit | 4.92 | 4.76 | 5.93 | 4.47 | 4.56 | 1.50 | 1.18 |
| Net profit margin | +6.8% | +7.6% | +8.8% | +7.7% | +6.2% | +3.5% | +4.1% |
| EPS (₹) | 4.45 | 4.32 | 5.20 | 5.58 | 14.33 | 6.45 | 5.35 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 11.05 | 11.05 | 11.05 | 8.05 | 2.30 | 2.30 | 2.30 |
| Reserves & surplus | 46.77 | 41.98 | 37.22 | 3.47 | 4.80 | 2.51 | 1.40 |
| Shareholders' funds (net worth) | 57.82 | 53.03 | 48.27 | 20.99 | 7.10 | 4.81 | 3.70 |
| Secured loans | 8.77 | 10.58 | 11.17 | 10.66 | 7.39 | 6.68 | 5.12 |
| Unsecured loans | 3.32 | 9.55 | 0.00 | 0.00 | 0.00 | 0.00 | 2.12 |
| Total debt | 12.09 | 20.13 | 11.17 | 10.66 | 7.39 | 6.68 | 7.24 |
| Total liabilities | 70.00 | 73.29 | 59.56 | 31.73 | 14.49 | 11.49 | 10.94 |
| Assets | |||||||
| Gross block | 29.25 | 25.49 | 24.05 | 17.96 | 11.04 | 7.45 | 7.48 |
| Net block | 18.08 | 16.66 | 17.67 | 14.09 | 8.80 | 6.42 | 6.41 |
| Capital work in progress | 1.71 | 0.20 | 0.05 | 0.04 | 0.00 | 0.00 | 0.00 |
| Investments | 12.18 | 13.33 | 11.50 | 4.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 15.28 | 10.18 | 11.02 | 9.58 | 5.39 | 3.80 | 2.32 |
| Sundry debtors | 28.79 | 24.68 | 22.01 | 11.50 | 12.54 | 6.27 | 8.48 |
| Cash & bank balances | 0.34 | 0.45 | 0.64 | 9.60 | 0.03 | 0.02 | 0.04 |
| Loans & advances | 18.00 | 19.59 | 13.07 | 5.94 | 9.54 | 3.94 | 2.08 |
| Total current assets | 62.41 | 54.90 | 46.74 | 36.62 | 27.50 | 14.03 | 12.92 |
| Total current liabilities | 24.61 | 12.00 | 16.52 | 23.05 | 21.64 | 10.81 | 10.43 |
| Net working capital | 37.80 | 42.90 | 30.22 | 13.57 | 5.86 | 3.22 | 2.49 |
| Total assets | 70.00 | 73.29 | 59.56 | 31.73 | 14.49 | 11.49 | 10.94 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.45 | 0.64 | 9.60 | 0.03 | 0.02 | 0.04 | - |
| Net cash from operating activities | 12.14 | (6.10) | (19.75) | 8.54 | 3.58 | 2.22 | - |
| Net cash from investing activities | (2.30) | (1.89) | (12.53) | (10.93) | (3.28) | (1.07) | - |
| Net cash from financing activities | (9.94) | 7.79 | 23.32 | 11.97 | (0.30) | (1.17) | - |
| Net change in cash | (0.11) | (0.20) | (8.96) | 9.57 | 0.00 | (0.02) | - |
| Closing cash | 0.34 | 0.45 | 0.64 | 9.60 | 0.03 | 0.02 | - |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +15.2% | -7.1% | +15.8% | -20.7% | +68.4% | +51.5% | - |
| EBITDA growth | +18.9% | -23.2% | +21.3% | +33.2% | +115.3% | +45.0% | - |
| PBT growth | +8.1% | -17.5% | +30.8% | +26.9% | +212.0% | +22.0% | +64.0% |
| Net income growth | +3.4% | -19.7% | +32.7% | -2.0% | +204.0% | +27.1% | - |
| Revenue CAGR (3Y) | +7.4% | -5.2% | +15.6% | +26.4% | +46.2% | - | - |
| EBITDA CAGR (3Y) | +3.5% | +7.5% | +51.5% | +60.8% | +47.1% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +6.8% | +7.7% | +8.6% | +7.7% | +4.5% | +3.5% | +4.3% |
| Return on capital employed | - | +11.4% | +19.2% | +29.7% | +54.7% | +18.6% | +15.9% |
| Return on net worth | - | +9.4% | +16.6% | +32.0% | +76.9% | +34.8% | +51.0% |
| Debt / equity | - | 0.31 | 0.32 | 0.64 | 1.18 | 1.64 | 3.33 |
| Long-term debt / equity | - | 0.10 | 0.16 | 0.27 | 0.64 | 1.63 | 3.14 |
| Interest cover | 27.04 | 22.50 | 13.65 | 13.64 | 11.49 | 34.66 | 40.66 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 2.52 | 3.19 | 4.00 | 7.91 | 5.82 | 3.52 |
| Inventory turnover | - | 5.88 | 6.52 | 7.75 | 15.92 | 14.20 | 13.07 |
| Debtors turnover | - | 2.67 | 4.01 | 4.82 | 7.78 | 5.89 | 4.36 |
| EPS (₹) | 4.45 | 4.32 | 5.20 | 5.58 | 14.33 | 6.45 | 5.35 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 47.99 | 43.69 | 14.31 | 30.87 | 20.90 | 16.08 |
To see the full year-wise statements and ratios of Sotac Pharmaceuticals Limited, buy the company report.
Board of directors of Sotac Pharmaceuticals Limited
Sotac Pharmaceuticals has 7 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Chetankumar Bachubhai Patel Also directs: Sotac Healthcare Private Limited, Sotac Research Private Limited | Director | 18 Dec 2015 | 10 Years 10 Months | Current |
| Dineshkumar Babulal Gelot Also directs: Sotac Healthcare Private Limited, Sotac Research Private Limited | Whole-Time Director | 12 Dec 2022 | 3 Years 10 Months | Current |
| Sharadkumar Dashrathbhai Patel Also directs: Sotac Healthcare Private Limited, Sotac Research Private Limited, Sotac Lifesciences Private Limited and 1 more | Managing Director | 12 Dec 2022 | 3 Years 10 Months | Current |
| Vishalkumar Patel | Director | 18 Dec 2015 | 10 Years 10 Months | Current |
| Dimpalben Dhebarbhai Patel | Director | 24 May 2025 | 1 Years 5 Months | Current |
| Bhavinkumar Prafulbhai Joshi | Director | 28 Aug 2024 | 2 Years 1 Months | Current |
Showing 6 of 7 current directors. View all directors
Peer comparison
Sotac Pharmaceuticals Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Pharma Impex Laboratories Pvt Ltd | ₹101.54 Cr (FY 2024) | 12.0% | Kolkata, West Bengal, India | |||
| Samrudh Pharmaceuticals Private Limited | ₹101.47 Cr (FY 2025) | 16.0% | Mumbai, Maharashtra, India | |||
| Sotac Pharmaceuticals Limitedthis company | ₹101.24 Cr (FY 2026) | ₹5.76 Cr | 5.7% | 4.4% | Sanand, Gujarat, India | |
| Nabros Pharma Private Limited | ₹101.03 Cr (FY 2025) | 6.0% | Ahmedabad, Gujarat, India | |||
| Instapill Private Limited | ₹100.92 Cr (FY 2025) | 11.0% | Bangalore, Karnataka, India | |||
| Lake Chemicals Private Limited | ₹100.59 Cr (FY 2025) | -5.0% | Bangalore, Karnataka, India | |||
| Credo Life Sciences Private Limited | ₹100.47 Cr (FY 2024) | 22.0% | Hyderabad, Telangana, India | |||
| Consern Pharma Limited | ₹100.37 Cr (FY 2025) | -2.0% | Ludhiana, Punjab, India | |||
| Medibios Laboratories Limited | ₹100.12 Cr (FY 2023) | -2.0% |
To see the full peer comparison of Sotac Pharmaceuticals Limited, buy the company report.
Charges & borrowings
Open charges
₹13.63 Cr
Satisfied charges
₹12.19 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 23 Jan 2025 | 101036625 | Hdfc Bank Limited | ₹29.5 Lakh | Open | |
| 16 Jul 2021 | 100472992 | Axis Bank Limited | ₹13.33 Cr | Open | |
| 24 Sep 2021 | 100481292 | Sidbi | ₹1 Cr | Satisfied | |
| 14 Aug 2020 | 100357907 | Sidbi | ₹50 Lakh | Satisfied | |
| 18 May 2016 | 100030818 | State Bank of India | ₹3.9 Cr | Satisfied |
To see the full charge records of Sotac Pharmaceuticals Limited, buy the company report.
Total charge records: 6 View all charges
Deals & funding
Sotac Pharmaceuticals Limited has 4 deals on record (1 secondary share transfer, 1 funding round, 1 ipo), with disclosed funding of ₹1.02 Cr; the latest was in April 2023.
Total deals
4
Secondary share transfer
1
Funding round
1
IPO
1
Rights issue
1
Disclosed funding
₹1.02 Cr
Deals on record (4 of 4)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Apr 2023 | IPO | ₹33.3 Cr | Investors: IPO Shareholders - Sotac Pharmaceuticals Limited, NAV Capital VCC -NAV Capital Emerging Star Fund, Ag Dynamic Funds Limited |
| Mar 2021 | Secondary share transfer | Undisclosed | Buyer: 3 individuals Seller: 4 individuals |
| Mar 2020 | Rights issue | ₹1.35 Cr | Investors: 4 individuals |
| Sep 2016 | Funding round | ₹1.02 Cr | Investors: 4 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Sotac Pharmaceuticals Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
Sotac Pharmaceuticals Limited has 3 MSME Form 1 returns on record for the period ending Mar 2024, listing 146 overdue payments to 28 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 28)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Himalayan Packaging Industries Private Limited | |||
| an individual supplier | |||
| an individual supplier | |||
| Vikram Thermo (India) Limited | |||
| Rakesh Chemicals Chhatral |
To see the full MSME payment records of Sotac Pharmaceuticals Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
Sotac Pharmaceuticals has 2 GST registrations: 1 active and 1 cancelled or inactive.
Total GSTINs
2
Active
1
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAWCS5135M1ZP | Gujarat | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Sotac Pharmaceuticals Limited, buy the company report.
Recent activity
Sotac Pharmaceuticals Limited has 14 board changes on record since 2015: 8 appointments and 6 cessations. The latest: Dimpalben Dhebarbhai Patel ceased to be Additional Director on 28 Sep 2025.
Filing
Sotac Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Charges
A charge registered on 24 Sep 2021 via Charge ID 100481292 with Sidbi was fully satisfied on 19 Mar 2026.
AGM
Sotac Pharmaceuticals Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Ceased
Dimpalben Dhebarbhai Patel ceased to be Additional Director.
Charges
A charge registered on 14 Aug 2020 via Charge ID 100357907 with Sidbi was fully satisfied on 04 Aug 2025.
Appointed
Dimpalben Dhebarbhai Patel was appointed as Director.
Ceased
Heena Viral Patel ceased to be Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.30 Cr with Charge ID 101036625 was registered on 23 Jan 2025.
Ceased
Bhavinkumar Prafulbhai Joshi ceased to be Additional Director.
Ceased
Ketankumar Arvindbhai Modi ceased to be Additional Director.
Appointed
Ketankumar Arvindbhai Modi was appointed as Director.
Appointed
Bhavinkumar Prafulbhai Joshi was appointed as Director.
17 earlier events are in the company report.
Frequently asked questions
Sotac Pharmaceuticals is an active public limited company based in Sanand, Gujarat, India. The company works in chemical products, within the chemicals industry. It was incorporated on 18 December 2015 (11+ years old) and is registered under CIN L24230GJ2015PLC085451. Listed on NSE: SOTAC.
Sotac Pharmaceuticals reported revenue of ₹101.24 Cr for FY 2025-26 (up 4.4% YoY) based on consolidated financials.
Sotac Pharmaceuticals has 7 current directors:
- Sharadkumar Dashrathbhai Patel - Managing Director
- Dineshkumar Babulal Gelot - Whole-Time Director
- Chetankumar Bachubhai Patel - Director
- Vishalkumar Patel - Director
- Dimpalben Dhebarbhai Patel - Director
- Bhavinkumar Prafulbhai Joshi - Director
- Ketankumar Arvindbhai Modi - Director
The latest financial statements of Sotac Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 29 September 2025. Year-wise statements from FY 2016 are in the company report.
The GSTIN of Sotac Pharmaceuticals is 24AAWCS5135M1ZP, registered in Gujarat. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Sotac Pharmaceuticals is L24230GJ2015PLC085451. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Sotac Pharmaceuticals is a listed company as per MCA records. Its shares are listed on NSE (symbol: SOTAC).
Sotac Pharmaceuticals was incorporated on 18 December 2015, making it 11+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Sotac Pharmaceuticals has 4 deals on record (1 secondary share transfer, 1 funding round, 1 ipo), with disclosed funding of ₹1.02 Cr; the latest was in April 2023.
The peers of Sotac Pharmaceuticals by revenue are Pharma Impex Laboratories Pvt Ltd, Samrudh Pharmaceuticals Private Limited, Nabros Pharma Private Limited, Instapill Private Limited, Lake Chemicals Private Limited and 3 more, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Dimpalben Dhebarbhai Patel ceased to be Additional Director on 28 Sep 2025. Dimpalben Dhebarbhai Patel was appointed as Director on 24 May 2025. Heena Viral Patel ceased to be Director on 01 Mar 2025. Sotac Pharmaceuticals has 14 board changes on record in total.
Yes, Sotac Pharmaceuticals is registered as a medium enterprise under Udyam registration (number: UDYAM-GJ-01-0012433).